|
Novavax, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, which specializes in creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases.〔(【引用サイトリンク】title=About Us )〕 The company has recombinant vaccine design and manufacturing technology and adjuvant technology. ==Pipeline== The company has run 14 clinical trials as of 30 April 2014.〔(【引用サイトリンク】title=Clinical Trials )〕 11 trials are completed.〔(【引用サイトリンク】title=Novavax Clinical trials )〕 The company announced preliminary positive safety and immunogenicity data for its RSV vaccine candidate in its Phase 2 clinical trial in women of childbearing age. In 2011, Novavax was awarded a $97 million contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop influenza vaccines.〔(【引用サイトリンク】title=Advanced Development of Recombinant Influenza Vaccine Products and Manufacturing Capabilities for Pandemic Preparedness )〕 The BARDA contract which was originally intended to develop a vaccine for H5N1 avian influenza, was redirected to H7N9 avian influenza due to H7N9's higher case count, and Novavax subsequently published data in the New England Journal of Medicine indicating high levels of immunogenicity with its virus-like particle (VLP) vaccine.〔(【引用サイトリンク】title=A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine )〕〔(【引用サイトリンク】title=New England Journal of Medicine Publishes Positive Data From Clinical Trial of Novavax' Vaccine Against H7N9 Avian Flu )〕 In April 2014, a team from Novavax and the University of Maryland published data on a vaccine candidate for MERS-CoV.〔(【引用サイトリンク】title=Mers vaccine helps mice fight off deadly virus )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Novavax」の詳細全文を読む スポンサード リンク
|